Popular terms

Dimethyl topics
Physiologic
Hydrochloric Acid
Fresnel Zone
Aberration
Ophthalmic
Liquid Crystal
Imaging System
Pharmaceutically Acceptable Salt
Pharmaceutically Acceptable Salts
Chloric Acid
Tartaric Acid
Fumaric Acid
Antagonist
Bradykinin
Enantiomer

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Dimethyl patents



      

This page is updated frequently with new Dimethyl-related patent applications.




Date/App# patent app List of recent Dimethyl-related patents
07/21/16
20160208117 
 Radiation curable compositions for food packaging patent thumbnailRadiation curable compositions for food packaging
An inkjet printing method includes the steps of jetting ink dots on a substrate of a plurality of radiation curable inkjet inks having a viscosity of no more than 50 mpa·s at 25° c. And a shear rate of 90 s−1, the plurality of radiation curable inkjet inks including a) at least one non-polymerizable, non-polymeric bisacylphosphine oxide present in a concentration of no more than 4.0 wt % based on the total weight of radiation curable inkjet ink; b) at least one monomer including at least one vinyl ether group and at least one polymerizable group selected from the group consisting of an acrylate group and a methacrylate group; and c) at least one polymerizable or polymeric thioxanthone, with the proviso that if the at least one polymerizable or polymeric thioxanthone contains no tertiary amine group that the radiation curable composition further includes at least one tertiary amine co-initiator selected from the group consisting of ethylhexyl-4-dimethylaminobenzoate, a polymerizable co-initiator containing a tertiary amine and a polymeric co-initiator containing a tertiary amine; and (2) fully curing the jetted ink dots using one or more uv leds..
Agfa Graphics Nv


07/21/16
20160207874 
 Improved process for the reductive amination and selective hydrogenation of substrates containing a selected halogen patent thumbnailImproved process for the reductive amination and selective hydrogenation of substrates containing a selected halogen
Disclosed is a process for performing a chemical reaction selected from reductive amination and hydrogenation of a first functional group in an organic feed substrate, which feed substrate comprises at least one further functional group containing a halogen atom, wherein the halogen atom is selected from the list consisting of chlorine, bromine, iodine, and combinations thereof, in the presence of hydrogen and a heterogeneous catalyst comprising at least one metal from the list of pd, rh, and ru, together with at least a second metal from the list consisting of ag, ni, co, sn, cu and au. The process is preferably applied for the reductive amination of 2-chloro-benzaldehyde to form 2-chloro-benzyldimethylamine, as an intermediate in the production of agrochemically active compounds and microbiocides of the methoximinophenylglyoxylic ester series.
Taminco Bvba


07/21/16
20160207242 
 Highly modified polyesters for containers patent thumbnailHighly modified polyesters for containers
A polyester resin for use in a process in which, during an expansion step, an incompressible fluid is injected through an opening of a preform, formed of the polyester resin, to form a container. The polyester resin includes a crystallizable polyester polymer wherein the polyester polymer is comprised of acid moieties and glycol moieties, with at least 85% of the total moles of acid moieties being terephthalate derived from terephthalic acid or its dimethyl ester and at least 85% of the total moles of glycol moieties derived from ethylene glycol.
Discma Ag


07/21/16
20160206587 
 Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose patent thumbnailPharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
The present invention relates to pharmaceutical compositions containing dimethyl fumarate (dmf), more specifically, the present invention relates to a pharmaceutical composition for oral use in treating hyperproliferative, inflammatory or autoimmune disorders by administering a low daily dosage in the range of 410 mg±5% or 400 mg±5% dimethyl fumarate, wherein the pharmaceutical formulation is in the form of an erosion matrix tablet.. .
Forward Pharma A/s


07/21/16
20160206586 
 Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose patent thumbnailPharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
The present invention relates to pharmaceutical compositions containing dimethyl fumarate (dmf). More specifically, the present invention relates to a pharmaceutical composition for oral use in treating psoriasis by administering a low daily dosage in the range of 375 mg±5% dimethyl fumarate, wherein the pharmaceutical formulation is in the form of an erosion matrix tablet..
Forward Pharma A/s


07/14/16
20160203809 
 Capacitive micro-machined ultrasound transducer cell patent thumbnailCapacitive micro-machined ultrasound transducer cell
The invention relates to a capacitive micro-machined ultrasound transducer (cmut) cell (6) comprising a cell floor (31) having a first electrode (7); a cell membrane (5) having a second electrode (7′) which opposes the first electrode and vibrates during transmission or reception of acoustic energy; a transmitter/receiver coupled to the first and second electrodes which causes the cell membrane to vibrate at an acoustic frequency and/or receives signals at an acoustic frequency; and an acoustic lens (13), overlaying the cell membrane, and having an inner surface opposing the cell membrane and an outer, patient-facing surface. According to the present invention the acoustic lens comprises at least one layer of a material selected from the group of: polybudatiene, polyether block amide (pebax), polydimethylsiloxane (pdms) and buthylrubber..
Koninklijke Philips N.v.


07/14/16
20160201269 
 High molecular weight and high cationic charge glyoxalated polyacrylamide copolymers and their methods of manufacture and use patent thumbnailHigh molecular weight and high cationic charge glyoxalated polyacrylamide copolymers and their methods of manufacture and use
A cellulose reactive glyoxalated copolymer composition and methods of producing and using the glyoxalated copolymer composition to, for instance, strengthen paper or board are discussed. A glyoxalated copolymer composition includes an aqueous medium containing a glyoxalated copolymer, wherein the glyoxalated copolymer is obtained by reaction in an aqueous reaction medium of a dry weight ratio of glyoxalxationic copolymer.
Basf Se


07/14/16
20160200924 
 Radiation curable compositions for food packaging patent thumbnailRadiation curable compositions for food packaging
A radiation curable inkjet ink set includes at least a cyan radiation curable inkjet ink, a magenta radiation curable inkjet ink, a yellow radiation curable inkjet ink, and a black radiation curable inkjet ink, each having a viscosity of no more than 50 mpa·s at 25° c. And a shear rate of 90 s-1 and containing: a) at least one non-polymerizable, non-polymeric bisacylphosphine oxide present in a concentration of no more than 4.0 wt % based on the total weight of the radiation curable composition; b) at least one monomer including at least one vinyl ether group and at least one polymerizable group selected from the group consisting of an acrylate group and a methacrylate group; and c) at least one polymerizable or polymeric thioxanthone, with the proviso that if the at least one polymerizable or polymeric thioxanthone contains no tertiary amine group that the radiation curable composition further includes at least one tertiary amine co-initiator selected from the group consisting of ethylhexyl-4-dimethylaminobenzoate, a polymerizable co-initiator containing a tertiary amine and a polymeric co-initiator containing a tertiary amine..
Agfa Graphics Nv


07/14/16
20160200923 
 Radiation curable compositions for food packaging patent thumbnailRadiation curable compositions for food packaging
A radiation curable inkjet ink set containing a plurality of inkjet inks having a viscosity of no more than 50 mpa·s at 25° c. And a shear rate of 90 s-1, each of the inkjet inks including a) at least one non-polymerizable, non-polymeric bisacylphosphine oxide present in a concentration of no more than 4.0 wt % based on the total weight of the inkjet ink; b) at least one monomer including at least one vinyl ether group and at least one polymerizable group selected from the group consisting of an acrylate group and a methacrylate group; and c) at least one polymerizable or polymeric thioxanthone, with the proviso that if the at least one polymerizable or polymeric thioxanthone contains no tertiary amine group, then the inkjet ink further includes at least one tertiary amine co-initiator selected from the group consisting of ethylhexyl-4-dimethylaminobenzoate and a polymerizable co-initiator containing a tertiary amine..
Agfa Graphics Nv


07/14/16
20160200700 
 Methods of producing alkylfurans patent thumbnailMethods of producing alkylfurans
Provided herein are methods of producing dialkylfurans, such as 2,5-dimethylfuran, and other alkyl furans, such as 2-methylfuran. For example, 2,5-dimethylfuran may be produced by reducing (5-methylfuran-2-yl)methanol or 2-(chloromethyl)-5-methylfuran..
Micromidas, Inc.


07/14/16
20160200699 

Glycidol preparation


This invention relates to an improved one-pot synthetic process for the preparation of glycidol from the reaction of glycerol and dimethyl carbonate. More specifically, the invention relates to a one-pot synthetic process for the preparation of glycidol comprising the reaction of glycerol and dimethyl carbonate in the presence of an ionic liquid catalyst having the formula: [cat+][x] wherein: [cat] represents one or more cationic species, and [x] represents one or more anionic species; wherein the reaction is conducted at a temperature of from 100° c.

07/14/16
20160200690 

Production 3,3-dimethyl-3,4-dihydro-1h-quinoxalin-2-one derivative and intermediate for said production method


Reducing the compound represented by formula (3) or the salt thereof to obtain the compound represented by formula (1) or the salt thereof.. .

07/14/16
20160200671 

Crystalline salts of (4s, 4as, 5ar, 12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide and methods of using the same


A crystalline mono hydrochloride salt of (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide is disclosed having improved stability. In addition, a crystalline mono mesylate salt and crystalline mono sulfate salt of (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide are also disclosed having improved stability.
Paratek Pharmaceuticals, Inc.


07/14/16
20160199353 

3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)


Disclosed are novel pharmaceutical compositions containing 3′-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazinol-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.. .
Novartis Ag


07/14/16
20160199349 

Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative


The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient, which is selected from (1r,4r)-6′-fluoro-n,n-dimethyl-4-phenyl-4′,9′-dihydro-3′h-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient, which is a propionic acid derivative selected from the group consisting of ibuprofen, naproxen, ketoprofen, flurbiprofen, fenoprofen, fenbufen, suprofen, pirprofen, indoprofen, tiaprofenic acid, oxaprozin, ibuproxam, flunoxaprofen, alminoprofen, naproxcinod, and the physiologically acceptable salts thereof.. .
Gruenenthal Gmbh


07/14/16
20160198719 

Synergistic antimicrobial composition


A synergistic antimicrobial composition having two components. The first component is a hydroxymethyl-substituted phosphorus compound.
Dow Global Technologies Llc


07/14/16
20160198716 

Method for producing emulsifiable pesticide solutions


The current invention provides a kit of parts for producing an emulsifiable pesticide solution comprising: (a) a water miscible organic solvent selected from the list of a glycol ether, a glycerol formal, dimethylsulfoxide, gamma-butyrolactone or mixtures thereof, (b) an alkoxylated alcohol with an average of 6 to 80 moles of ethylene oxide and 2 to 60 moles of propylene oxide per mole of alcohol; and (c) a pesticidal active ingredient. The invention further provides a composition for producing an emulsifiable pesticide solution, a method for producing such a composition and a method for treating an agricultural crop.
Arysta Lifescience Benelux Sprl


07/07/16
20160197280 

Composition comprising polymeric organic semiconducting compounds


The present invention relates to novel compositions comprising one or more polymeric organic semiconducting (osc) compounds and one or more organic solvents. The composition preferably comprises 3,4-dimethyl anisole as solvent.
Merck Patent Gmbh


07/07/16
20160194478 

Heat stabilizer for halogen-containing polymers


A stabilizer composition having low volatility and high efficiency comprising: (i.) 25.000% to 99.997% by weight of at least one dimethyltin compound of formula (ch3)2sn(s(ch2)mcoor1)2 wherein r1 is a linear, branched or cyclic c10-c20 alkyl group and m is 1 or 2, optionally containing unsaturations in the form of double or triple bonds; (ii.) 0.001% to 50.000% by weight of at least one mono-methyltin compound of formula ch3sn(s(ch2)ncoor2)3 wherein r2 is a linear, branched or cyclic c10-c20 alkyl group and n is 1 or 2, optionally containing unsaturations in the form of double or triple bonds; (iii.) 0.001% to 10.000% by weight of at least one tri-methyltin compound of formula (ch3)3sn(s(ch2)pcoor3) wherein r3 is a linear, branched or cyclic c10-c20 alkyl group and p is 1 or 2, optionally containing unsaturations in the form of double or triple bonds; and (iv.) 0.001% to 15.000% by weight of at least one thioester of formula hs(ch2)qcoor4 wherein r4 is a linear, branched or cyclic c10-c20 alkyl group and q is 1 or 2, optionally containing unsaturations in the form of double or triple bonds.. .
Galata Chemicals Llc


07/07/16
20160193795 

Polydimethylsiloxane sheet, optical element incorporating the same, and manufacturing method thereof


A method of manufacturing a pdms sheet that ensures good adhesion, handleability and stability to metal thin films or metal patterns of any desired shape. Given a low-molecular-weight siloxane of a cyclic structure represented by [—si(ch3)2o—]k where k is an integer of 3 to 20 inclusive, the polydimethylsiloxane sheet has a structure where the content of the low-molecular-weight siloxane at the pattern-formation surface is more than that of the low-molecular-weight siloxane at the base surface, and a spacing between the adjacent metal patterns is variable by deformation of the polydimethylsiloxane sheet..
Dai Nippon Printing Co., Ltd.


07/07/16
20160193236 

Gold(i) complexes with t-butyl phosphine and dialkyl dithiocarbamate ligands


Gold(i) complexes of formulae [au{p(t-bu)3}(s2cn(ch3)2)] (1), and [au{p(t-bu)3}(s2cn(c2h5)2)] (2) have been prepared by the reaction of equimolar amounts of [au{p(t-bu)3}(cl)] with sodium dimethyldithiocarbamate monohydrate, and sodium diethyldithiocarbamate trihydrate respectively. Both complexes (1) and (2) are iso-structural having linear geometry.
King Abdulaziz City For Science And Technology


07/07/16
20160193183 

Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and a gabapentinoid


The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6′-fluoro-n,n-dimethyl-4-phenyl-4′,9′-dihydro-3′h-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient selected from gabapentinoids and the physiologically acceptable salts thereof.. .
Gruenenthal Gmbh


06/30/16
20160187348 

Methods for detecting renal disease


The disclosure is directed to methods and apparatus for the determination, diagnosis, progression and prognosis of kidney disease and mortality associated with kidney disease. The disclosure includes methods for determining renal function, in particular estimating glomerular filtration rate (gfr), in an animal.

06/30/16
20160186161 

Alkenol dehydratase variants


Described are alkenol dehydratase variants having improved activity in catalyzing the conversion of a compound corresponding to the general formula cnh2no into cnh2n-2+h2o with 3<n<7. In particular, described are alkenol dehydratase variants having, e.g., an improved activity in converting but-2-en-1-ol (crotyl alcohol) into 1,3 butadiene and/or an improved activity in converting but-3-en-2-ol into 1,3 butadiene and/or an improved activity in converting 3-methylbut-2-en-1-ol (prenol) or 3-methylbut-3-en-2-ol (isoprenol) into isoprene and/or an improved activity in converting 2,3-dimethyl-but-2-en-1-ol into dimethyl-butadiene..

06/30/16
20160186042 

Enhanced oil recovery process


A process is provided for recovering oil from a hydrocarbon-bearing formation comprised of hydrocarbons and formation water. The process presented herein includes an oil recovery formulation comprising at least 75 mol % dimethyl sulfide and between 1 mol % and 18 mol % of dimethyl ether, wherein the amount of dimethyl ether in the oil recovery formulation is selected relative to the solubility of dimethyl ether in the formation water..

06/30/16
20160185937 

Polyolefin composition and process for preparing the same


A polyolefin composition comprises (a) a polypropylene polymer, (b) 1,3:2,4-bis-o-[(3,4-dimethylphenyl)methylene]-d-glucitol, and (c) 1,3:2,4-bis-o-[(3,4-dichlorophenyl)methylene]-d-glucitol. A method for producing a polyolefin composition comprises the steps of (a) providing a polypropylene polymer; (b) providing 1,3:2,4-bis-o-[(3,4-dimethylphenyl)methylene]-d-glucitol; (c) providing 1,3:2,4-bis-o-[(3,4-dichlorophenyl)methylene]-d-glucitol; (d) mixing the 1,3:2,4-bis-o-[(3,4-dimethylphenyl)methylene]-d-glucitol and the 1,3:2,4-bis-o-[(3,4-dichlorophenyl)methylene]-d-glucitol with the polypropylene polymer to produce a mixture; (e) heating the mixture to a temperature equal to or greater than the melting point of the polypropylene polymer; and (f) cooling the heated mixture to a temperature below the melting point of the polypropylene polymer, thereby producing a polyolefin composition..

06/30/16
20160185902 

Continuous reaction device for synthesizing polyoxymethylene dimethyl ethers


The present invention pertains to the technical field of energy resource chemical industry, and in particular relates to a continuous reaction device and process for synthesizing polyoxymethylene dimethyl ethers by using paraformaldehyde and methylal as feedstock or using trioxane and methylal as feedstock in the presence of an acidic catalyst. The continuous reaction device comprises multiple slurry bed stirred tank reactors connected in series or in combination of series connection and parallel connection, and also comprises an on-line solid-liquid separation device to perform separation of the reaction mixture from the catalyst.

06/30/16
20160185709 

Method of making a templating agent


A method for preparing 1-adamantyltrimethylammonium methylcarbonate or n,n-dimethyl-3,5-dimethylpiperidinium methylcarbonate is disclosed. The method comprises reacting dimethyl carbonate and 3,5-dimethylpiperidine or a 1-adamantylamine compound and in the presence of water in a sealed vessel at a temperature of from 80 to 200° c.

06/30/16
20160184808 

Process for preparing zeolite beta and use thereof


Method for preparing zeolite beta which method comprises crystallization of zeolite beta from a solution comprising a template, a silicon source and an aluminum source in which the template is polymeric compound comprising ionizable polydiallyldimethylammonium (pdadma) cationcrystallization. Furthermore, the present invention provides the use of thus prepared zeolite beta in catalysts for hydrocarbon conversions..

06/30/16
20160183518 

Lactofen and dicamba diglycol amine liquid formulations


The present invention relates to liquid agricultural formulations comprising from about 15 to about 40% w/w dicamba diglycol amine, from about 1 to about 15% w/w lactofen, from about 5 to about 40% w/w of a solvent selected from the group consisting of: (1) a solvent comprising dimethyl glutarate, dimethyl succinate, and dimethyl adipate; and (2) a solvent comprising a mixture of aromatic hydrocarbons obtained from distillation of aromatic streams derived from crude oil, from about 0.5 to about 5% w/w of a thickener with the chemical formula (mg,al)5si8o20×4h2o, and from about 2 to about 15% w/w of a polyarylphenyl ether sulphate, ammonium salt surfactant, and methods of use thereof.. .

06/23/16
20160177106 

Hydrogen-bonding surfaces for ice mitigation


Various embodiments provide ice mitigating surface coatings and methods for applying ice mitigating surface coatings. Various embodiment ice mitigating surface coatings may be formed by hydrolysis of one or more substituted n-alkyldimethylalkoxysilanes terminated with functionalities having the following characteristics with respect to water: 1) non-polar interactions; 2) hydrogen bonding through donor and acceptor interactions; or 3) hydrogen bonding through acceptor interactions only.

06/23/16
20160177043 

Anion exchange membrane for electrodialysis applications and process for the preparation thereof


The present invention relates to the preparation of novel anion exchange membranes from bicomponent or tricomponent copolymers containing both quaternizable and cross-linkable moieties. The bicomponent copolymers consisted with polyacrylonitrile and poly(2-dimethylaminoethyl) methacrylate and the tricomponent copolymers consisted with polyacryloniterle and poly2-dimethylaminoethyl) methacrylate and polyn-butyl acrylate.

06/23/16
20160176891 

Conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents


Are provided. Pharmaceutical compositions comprising either the compound of formula i or formula ii are disclosed.

06/23/16
20160176776 

Conversion of oxygenates to aromatics


Described herein are processes for production of hydrocarbon products comprising contacting a feed comprising methanol and/or dimethyl ether with a catalyst composition, which comprises a zeolite having a constraint index from 1-12 and an active binder comprising a metal oxide with a dehydrogenation function, under conditions sufficient to form the hydrocarbon product, wherein the hydrocarbon product comprises aromatics, olefins, and/or paraffins. Also described herein are catalyst compositions comprising a zeolite having a 10-/12-membered ring framework and a microporous surface area of at least 150 m2/g, and from ˜1 wt % to ˜10 wt % of a zinc oxide binder, the catalyst composition having a zinc to aluminum atomic ratio from ˜0.08 to ˜8.5..

06/23/16
20160175309 

Polymorphs of arry-380, a selective her 2 inhibitor and pharmaceutical compositions containing them


Polymorphs of n4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-n6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein. Processes for preparing the polymorphs and pharmaceutical composition comprising the polymorphs are also disclosed..

06/23/16
20160174556 

Dermal compositions


Disclosed herein are veterinary compositions including imidacloprid or an analogue thereof; a pyrethroid; a solvent selected from the group consisting of n-methyl pyrrolidone, n-ethyl pyrrolidone and mixtures thereof; and dimethyl sulfoxide. The veterinary compositions of the invention are useful in methods of controlling parasites on or within warm-blooded domesticated animals..

06/16/16
20160172711 

Electrolyte and lithium based batteries


An example electrolyte includes a solvent mixture, a lithium salt, a non-polymerizing solid electrolyte interface (sei) precursor additive, and a solvent additive. The solvent mixture includes dimethyl carbonate (dmc) and fluoroethylene carbonate (fec) present in a volume to volume ratio ranging from 20 to 1 to 1 to 20.
Gm Global Technology Operations Llc


06/16/16
20160169098 

Lubrication oil and internal-combustion engine fuel


The lubrication oil is injected with lubrication oil impregnating agent composed of dimethylalkyl tertiary amine in the range from 0.01 to 1 volume % and desirably in the range from 0.1 to 0.5 volume %. Petroleum oil fuel is injected with fuel oil impregnating agent composed of dimethylalkyl tertiary amine in the range from 0.5 to 1 volume %.

06/16/16
20160168697 

Delivery device, manufacturing system and process of manufacturing


A delivery device, manufacturing system, and process of manufacturing are disclosed. The delivery device includes a feed tube and a chemical vapor deposition coating applied over an inner surface of the feed tube, the chemical vapor deposition coating being formed from decomposition of dimethylsilane.
Silcotek Corp.


06/16/16
20160168307 

Method for producing polyoxymethylene dimethyl ethers from feedstock of concentrated formaldehyde


The present invention pertains to the technical field of energy resource chemical industry, and in particular relates to a process for producing polyoxymethylene dimethyl ethers by directly using concentrated formaldehyde aqueous solution as feedstock to catalytically react with methanol and/or methylal in a fixed bed reactor. The method of the present invention uses concentrated formaldehyde aqueous solution with a concentration of over 80% by weight to react with methanol and/or methylal, in the presence of an acidic catalyst, to produce the required polyoxymethylene dimethyl ethers.
China University Of Petroleum (eastern China)


06/16/16
20160168182 

Method for the purification of decitabine


A method of preparing purified decitabine comprises mixing crude decitabine with solvent, such as dimethylacetamide, to form a solution or suspension and forming the purified decitabine from the solution or suspension. The forming step comprises adding an anti-solvent, such as ethanol, to the solution or suspension.
Johnson Matthey Public Limited Company


06/16/16
20160168109 

Method for producing n,n-dialkylhomofarnesic acid amide


Provided are: a method for producing n,n-dialkylhomofarnesic acid amide, which is a precursor of (±)-3a,6,6,9a-tetramethyldodecahydronaphtho[2.1-b]furan that is useful as a fragrance, at a high recovery rate of a raw material, at a high purity and at a high yield; and a method for producing (±)-3a,6,6,9a-tetramethyldodecahydronaphtho[2.1-b]furan. It is a method for producing n,n-dialkylhomofarnesic acid amide, said method including reacting nerolidol with n,n-dialkylformamide dimethyl acetal under the conditions that the n,n-dialkylformamide dimethyl acetal can be refluxed, wherein the molar ratio of the n,n-dialkylformamide dimethyl acetal to the nerolidol is in a range of 1.5 to 3..
Kao Corporation


06/16/16
20160168060 

Method for manufacturing methyl fluoride


An object of the present invention is to provide a method for producing methane fluoride that is useful, for example, as a dry etching gas, the method being more suitable for industrial production. To achieve this object, the present invention provides a method including reacting (a) dimethyl sulfate and (b) at least one fluorocompound in a liquid phase, the fluorocompound (b) being at least one compound selected from the group consisting of hydrogen fluoride and hydrofluoric acid salts, or a metal fluoride, wherein when the fluoride compound (b) includes hydrogen fluoride or a hydrofluoric acid salt, the reaction is carried out without a solvent or using a polar solvent as a solvent, and when the fluoride compound (b) is a metal fluoride, the reaction is carried out using water as a solvent..
Daikin Industries, Ltd.


06/09/16
20160160058 

Antimicrobial inks and sealants


Antimicrobial inks, sealants, coatings or varnishes that are manufactured in three distinct phases: phase 1, which is an oil phase comprising ethoxylate alcohol laureth 7, didecyldimethylammonium chloride, glutaric acid dialdehyde, pinus sylvestris, alkyldimemylberizylammonium chloride, parachlorometaxylenol, ethylenediaminetetraacetic acid, 2-hydroxypropanoic acid, hydroxy-9-cis-octadecenoic acid, cetyl alcohol wax, octadecenoic acid, palmityl alcohol, and epoxy-cis-9-octadecenoic acid; phase 2, which is a micro-emulsion phase comprising ethoxylate alcohol laureth-7, cetyl alcohol wax, pinus sylvestris, and propan-2-ol and phase 3, which combines the products of phases 1 and 2 with a base to produce the ink, sealant, coating or varnish.. .

06/09/16
20160158362 

Liquid bendamustine formulation


The present invention provides stable bendamustine-containing pharmaceutical compositions suitable for long term storage. The compositions include bendamustine, a pharmaceutically acceptable salt, and/or a hydrate form thereof, a solvent mixture of n,n-dimethylacetamide and glycerin, and an antioxidant.

06/02/16
20160157362 

Coating metal foil with n-heterocyclic carbene compounds containing organic functionalities for improving metal-to-resin adhesion


A carbene-coated metal foil is produced by applying an n-heterocyclic carbene (nhc) compound to one or more surfaces of a metal foil (e.g., an electrodeposited copper foil having a surface that is smooth and non-oxidized). The nhc compound contains a matrix-reactive pendant group that includes at least one of a vinyl-, allyl-, acrylic-, methacrylic-, styrenic-, amine-, amide- and epoxy-containing moiety capable of reacting with a base polymer (e.g., a vinyl-containing resin such as a polyphenylene oxide/triallyl-isocyanurate (ppo/taic) composition).
International Business Machines Corporation


06/02/16
20160157361 

Coating metal foil with n-heterocyclic carbene compounds containing organic functionalities for improving metal-to-resin adhesion


A carbene-coated metal foil is produced by applying an n-heterocyclic carbene (nhc) compound to one or more surfaces of a metal foil (e.g., an electrodeposited copper foil having a surface that is smooth and non-oxidized). The nhc compound contains a matrix-reactive pendant group that includes at least one of a vinyl-, allyl-, acrylic-, methacrylic-, styrenic-, amine-, amide- and epoxy-containing moiety capable of reacting with a base polymer (e.g., a vinyl-containing resin such as a polyphenylene oxide/triallyl-isocyanurate (ppo/taic) composition).
International Business Machines Corporation


06/02/16
20160155867 

Coating solution for forming light-absorbing layer, and producing coating solution for forming light-absorbing layer


A method of forming a coating solution for forming a light-absorbing layer of a solar cell, including dissolving a chalcogen and at least one metal or metal compound in dimethylsulfoxide and/or water in the presence of hydrazine to obtain a homogeneous hydrazine-coordinated metal chalcogenide complex solution; and adding at least one alcohol having 1 to 5 carbon atoms to the homogeneous hydrazine-coordinated metal chalcogenide complex solution.. .
Tokyo Ohka Kogyo Co., Ltd.


06/02/16
20160154328 

Electrophotographic photosensitive member, process cartridge and electrophotographic apparatus


To provide an electrophotographic photosensitive member that can allow a high-quality image, in which photomemory after repeated use in a high-speed process is suppressed, to be output, as well as a process cartridge and an electrophotographic apparatus including the electrophotographic photosensitive member. An electrophotographic photosensitive member wherein a charge generating layer includes a gallium phthalocyanine crystal in which an organic compound is contained, wherein the organic compound is at least one compound selected from the group consisting of dimethylsulfoxide, n,n-dimethylformamide, n-methylformamide, n-propylformamide, n-vinylformamide and n-methylpyrrolidone, the content of the organic compound is 0.1% by mass or more and 2.0% by mass or less based on a gallium phthalocyanine in the gallium phthalocyanine crystal, and a charge transporting layer includes a polycarbonate resin having structural units represented by the following formula (1)..
Canon Kabushiki Kaisha


06/02/16
20160154326 

Electrophotographic photosensitive member, producing electrophotographic photosensitive member, process cartridge and electrophotographic apparatus


The charge generating layer includes a gallium phthalocyanine crystal in which an organic compound (p) is contained, the organic compound (p) is at least one compound selected from the group consisting of dimethylsulfoxide, n,n-dimethylformamide, n-methylformamide, n-propylformamide, n-vinylformamide and n-methylpyrrolidone, the content of the organic compound (p) is 0.1% by mass or more and 1.5% by mass or less based on a gallium phthalocyanine in the gallium phthalocyanine crystal, and the charge transporting layer includes a resin having a siloxane structure, and a compound (q) having a boiling point of 150° c. Or more at 1 atm..
Canon Kabushiki Kaisha


06/02/16
20160152899 

Production of dimethyl ether


The present invention concerns the production and use of feedstock streams. Specifically, the present invention provides a process for the production of a commodity using two or more feedstock streams.

06/02/16
20160152537 

Systems and methods for manufacture of dimethyl ether (dme) from natural gas and flare gas feedstock


A unique design for a mobile system that reforms flare gas or natural gas, using air without steam, to directly produce dimethyl ether (dme), a diesel substitute, is disclosed. The system first reforms the air-methane mixture at ambient atmospheric pressures, and then compresses the resulting co-hydrogen-nitrogen gas mixture to up to 600 psi, and feeds it through a combined reactor which reacts the gas mixture directly into dimethyl ether.
Pioneer Energy Inc.


06/02/16
20160151309 

Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol


A pharmaceutical formulation for prolonged release of the active ingredient 3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof in a matrix containing between 1 and 80 wt % of at least one pharmaceutically acceptable hydrophilic or hydrophobic polymer as a matrix forming agent and exhibiting in vivo the following release rate: 3 to 35% by weight (based on 100% by weight active ingredient) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 0.5 hours; 5 to 50% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 1 hour; 10 to 75% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 2 hours; 15 to 82% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 3 hours; 30 to 97% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 6 hours; more than 50% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 12 hours; more than 70% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 18 hours, and more than 80% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 24 hours.. .
Gruenenthal Gmbh


06/02/16
20160150791 

Synergistic antimicrobial composition


A synergistic antimicrobial composition having two components. The first component is a hydroxymethyl-substituted phosphorus compound.
Dow Global Technologies Llc


05/26/16
20160148802 

Liquid chemical for forming protecting film


Disclosed is a liquid chemical for forming a water-repellent protecting film at least on a surface of a recessed portion of an uneven pattern at the time of cleaning a wafer having a finely uneven pattern at its surface and containing silicon at at least a part of the uneven pattern. This liquid chemical contains a silicon compound a represented by the general formula: r1asi(h)bx4-a-b and an acid a, the acid a being at least one selected from the group consisting of trimethylsilyl trifluoroactate, trimethylsilyl trifluoromethanesulfonate, dimethylsilyl trifluoroactate, dimethylsilyl trifluoromethanesulfonate, butyldimethylsilyl trifluoroactate, butyldimethylsilyl trifluoromethanesulfonate, hexyldimethylsilyl trifluoroacetate, hexyldimethylsilyl trifluoromethanesulfonate, octyldimethylsilyl trifluoroactate, octyldimethylsilyl trifluoromethanesulfonate, decyldimethylsilyl trifluoroacetate and decyldimethylsilyl trifluoromethanesulfonate..
Central Glass Company, Limited


05/26/16
20160146105 

Method and device for converting municipal waste into energy


A method and device for converting municipal waste into energy. This method involves heating the waste in multiple sections of a chamber to produce syngas and biochar.

05/26/16
20160145224 

Process for the preparation of an antidepressant and the intermediates thereof


The present invention relates to a process for the preparation of 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine of formula (i), also known as vortioxetine, salts thereof, and intermediates useful for its synthesis.. .
Dipharma Francis S.r.l.


05/26/16
20160144058 

Ir dyes for fluorescence imaging


A method for organ imaging, comprising: administering to a subject a diagnostic effective amount of 2-((e)-2-((e)-3-(2-((e)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-phenoxycyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3h-indol-1-ium-5-sulfonate or 2-((e)-2-((e)-3-(2-((e)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-(4-sulfonatophenoxy)cyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3h-indol-1-ium-5-sulfonate. In one embodiment, the organ includes one or more of kidney, bladder, liver, gall bladder, spleen, intestine, heart, lungs and muscle..
Ll-cor, Inc.


05/26/16
20160143913 

Combination


The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering n-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2h-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and n-{(1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, to a human in need thereof..
Novartis Ag


05/26/16
20160143883 

Method of treating thrombocytopenia


Invented is a method of treating thrombocytopenia in a human in need thereof which comprises the administration of a therapeutically effective amount of a 3′-{n′-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid to such human.. .
Novartis Ag


05/26/16
20160143820 

Colorful gel and preparation method thereof


The present invention provides a colorful gel, comprising following components by weight percentage: 20.0% to 25.0% by weight of glycerin, 20.0% to 25.0% by weight of propylene glycol, 1.0% by weight of sea algae extract, 0.05% by weight of disodium edta, 0.06% by weight of allantoin, 0.05% by weight of sodium hyaluronate, 20.0% to 30.0% by weight of cyclopentasiloxane, 5.0 to 10.0% by weight of dimethicone, 0.5 to 1.0% by weight of sodium acrylate/sodium acryloyldimethyl taurate copolymer, 0.25 to 0.5% by weight of isohexadecane, 0.2% to 0.4% by weight of polysorbate-80, 1.5% by weight of soluble collagen, 0.5% by weight of caprylyl glycol, and water as the rest. The present invention also provides a preparation method of the colorful gel.
Guangzhou Sheencolor Cosmetics Co., Ltd.


05/19/16
20160137894 

Non-azeotropic fluid mixture for air conditioning devices


The composition of the mixture contains at least one polymerisation inhibitor agent (hydroquinone, benzotriazole, dimethyl-t-butylphenol).. .

05/19/16
20160137844 

Carbazole dioxazine pigment and a its preparation


The pigment is synthesized from 3-nitro-n-ethylcarbazole. The first step is nitration of 3-nitro-n-ethylcarbazole to form 3,6-dinitro-n-ethylcarbazole which is reduced to form 3-amino-6-nitro-n-ethylcarbazole.

05/19/16
20160137683 

Method for preparing epirubicin and intermediate thereof


The present invention provides a method for preparing epirubicin and an intermediate adaptive to the method. The preparation method may include: reacting tert-butyldimethylsilyl chloride with n-trifluoroacetyl adriamycin to obtain a first compound n-trifluoroacetyl-14-o-tert-butyldimethylsilyl adriamycin; oxidizing the first compound to obtain a second compound 4′-ketone-n-trifluoroacetyl-14-o-tert-butyldimethylsilyladriamycin; reducing the second compound to obtain a third compound n-trifluoroacetyl-14-o-tert-butyldimethylsilyl epirubicin; and performing deprotection and hydrolysis reactions on the third compound to obtain epirubicin.
Zhejiang Hisun Pharmaceutical Co., Ltd.


05/19/16
20160137589 

Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease


New compound 4-[ethyl(dimethyl)ammonio]butanoate, method of preparation thereof and use in the treatment of cardiovascular disease.. .
Jsc Grindeks


05/19/16
20160137587 

Transition-metal-free n-arylation of tertiary amines using arynes


The present invention relates to transition-metal-free process for the synthesis of tertiary arylamines comprises coupling reaction between arynes and n,n-dimethyl aniline compounds in presence of 18-crown-6, kf and thf.. .
Council Of Scientific & Industrial Research


05/19/16
20160136280 

Stable intravenous formulation


A stable lyophilized formulation for intravenous administration of the compound 4-{[(2r, 3s, 55)-4-(4-chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)- pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid 1-[2-(2-methoxy-ethoxy)-ethoxycarbonyloxy]-ethyl ester is provided.. .
Hoffmann-la Roche Inc.


05/19/16
20160135477 

Ready-to-drink tea beverages with reduced benzene and methods for making same


A ready-to-drink tea beverage contains tea extract, aerated water and benzoate, such as a benzoic acid salt. The beverage and/or the aerated water can contain at least 5.0 ppm dioxygen (o2) and preferably at least about 5.0 ppm o2.

05/12/16
20160133672 

Hybrid perovskite with adjustable bandgap


A method is provided for preparing a thin film of perovskite material having an adjustable bandgap. The method forms a thin film of material having the formula bx2, where anionic part x is a halide, and where the cation b is lead (pb), tin (sn), or germanium (ge).
Sharp Laboratories Of America, Inc.


05/12/16
20160131985 

Electrophotographic photosensitive member, process cartridge, and electrophotographic apparatus


Provided is an electrophotographic photosensitive member, including in the following order: a support; a charge-generating layer; and a charge-transporting layer, in which: the charge-generating layer includes a gallium phthalocyanine crystal in which an organic compound is contained; the organic compound is at least one compound selected from the group consisting of dimethyl sulfoxide, n,n-dimethylformamide, n-methylformamide, n-propylformamide, n-vinylformamide, and n-methylpyrrolidone; a content of the organic compound is 0.1% by mass or more and 1.5% by mass or less with respect to a mass of gallium phthalocyanine in the gallium phthalocyanine crystal; and the charge-transporting layer comprises at least one compound selected from the group consisting of a compound represented by the formula (1), a compound represented by the formula (2), a compound represented by the formula (3), and a compound represented by the formula (4).. .
Canon Kabushiki Kaisha


05/12/16
20160131658 

Method and kit for assessing viable cells


The present invention provides simple, rapid methods and procedures for analyzing cells, hereunder quantitative and qualitative assessment of cells, such as viability. The present invention relates to the use of various optionally substituted reporter compounds particularly detectable upon their reaction with thiol-containing species present in higher concentrations in intact (e.g., living) cells than in non-intact (e.g., dead, stressed and apoptotic) cells.
Chemometec A/s


05/12/16
20160130272 

Crystalline forms of n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboximide for the treatment of myeloproliferative disorders


Crystalline form, form n-2, of n,ndicyclopropyl-4-(1,5-dimethyl-1hpyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide (compound i) is provided. Also provided are a pharmaceutical composition and an oral dosage form comprising form n-2 of compound i as well as a method of using the form n-2 of compound i in the treatment of myeloproliferative disorders, which include polycythaemia vera, thrombocythaemia and primary myelofibrosis..
Bristol-myers Squibb Company


05/12/16
20160129031 

Pyrazole derivative and use thereof for medical purposes


The present invention provides pyrazole derivatives, uses thereof for medical purposes and so on. More particularly, the present invention relates to pharmaceuticals useful for the prevention or treatment of constipation, which comprise as an active ingredient 3-(3-{4-[3-(β-d-glucopyranosyloxy)-5-isopropyl-1h-pyrazol-4-ylmethyl]-3-methylphenoxy}propylamino)-2,2-dimethylpropionamide, or a pharmaceutically acceptable salt thereof.
Kissei Pharmaceutical Co., Ltd.


05/12/16
20160129009 

High purity diaminophenothiazinium compounds including methylthioninium chloride (mtc)


This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiaziniumcompounds”) including methythioninium chloride (mtc) (also known as methylene blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (nos); nitrosyl reduction (nr); thiosulfonic acid formation (tsaf); oxidative coupling (oc); cr(vi) reduction (cr); isolation and purification of zwitterionic intermediate (iapozi); ring closure (rc); chloride salt-formation (csf); one of: sulphide treatment (st); dimethyldithiocarbamate treatment (dt); carbonate treatment (ct); ethylenediaminetetraacetic acid treatment (edtat); organic extraction (oe); and recrystallisation (rx).
Wista Laboratories Ltd.


05/12/16
20160129003 

Pharmaceutical combinations


A pharmaceutical combination comprising: (a) a phosphatidylinositol-3-kinase inhibitor selected from 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile, 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine, (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or any pharmaceutically acceptable salt thereof, and (b) an anaplastic lymphoma kinase inhibitor, particularly for use in the treatment or prevention of a proliferative disease; uses of such a combination in the treatment or prevention of proliferative diseases; to pharmaceutical compositions of the combination of said therapeutic agents and methods of treating a proliferative disease in a subject comprising administering to said subject a therapeutically effective amount of such a combination.. .
Novartis Ag


05/12/16
20160128952 

Pharmaceutical combination


A combination comprising as components (a) the compound 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol, and (b) paracetamol or a derivative thereof, a pharmaceutical formulation and a dosage form comprising said combination as well as a method of treating pain, e.g. Chronic or acute pain, characterized in that components (a) and (b) are administered simultaneously or sequentially to a mammal, wherein component (a) may be administered before or after component (b) and wherein components (a) or (b) are administered to the mammal either via the same or a different pathway of administration..
Gruenenthal Gmbh


05/05/16
20160124329 

Electrophotographic photosensitive member, process cartridge and electrophotographic apparatus, and chlorogallium phthalocyanine crystal and producing the same


An electrophotographic photosensitive member includes a support and a photosensitive layer in this order. The photosensitive layer contains a chlorogallium phthalocyanine crystal represented by formula (1) in which at least one organic compound selected from n,n-dimethylformamide and dimethyl sulfoxide is contained.
Canon Kabushiki Kaisha


05/05/16
20160124328 

Electrophotographic photosensitive member, process cartridge and electrophotographic apparatus


An electrophotographic photosensitive member wherein a charge generating layer of the electrophotographic photosensitive member includes a gallium phthalocyanine crystal in which an organic compound is contained, wherein the organic compound is at least one compound selected from the group consisting of dimethylsulfoxide, n,n-dimethylformamide, n-methylformamide, n-propylformamide, n-vinylformamide and n-methylpyrrolidone, the content of the organic compound is 0.1% by mass or more and 2.0% by mass or less based on a gallium phthalocyanine in the gallium phthalocyanine crystal, and a charge transporting layer of the electrophotographic photosensitive member includes a polycarbonate resin having structural units represented by formulae (1) and (2).. .
Canon Kabushiki Kaisha


05/05/16
20160122938 

Chemically stable, stain-, abrasion- and temperature-resistant, easy-to-clean metalware for use in elevated temperatures


A metalware for use in elevated temperatures, where the surface of the said ware is coated with a layer which is a hydrolysis and polycondensation product of a composition comprising tetraethoxy silane (teos), methyl trimethoxy silane (mtms), dimethyl siloxane (dms), inorganic filler and polar solvent where the said composition comprises 1,3-dialkyl imidazolium alkyl sulfate.. .
Eksen Makine Sanayi Ve Ticaret A.s.


05/05/16
20160122375 

Immobilized metathesis tungsten catalysts and use thereof in olefin metathesis


Compound of formula (i) wherein m is w; r1 is h, aryl, heteroaryl, alkyl, or heteroalkyl, optionally substituted, respectively; r2 and r3 can be the same or different and are alkyl, alkenyl, heteroalkyl, heteroalkenyl, aryl, or heteroaryl, optionally substituted, respectively, or hydrogen; r5 is a residue r6—x—, wherein r6 is alkyl, aryl, heteroalkyl, heteroaryl, optionally substituted, respectively; (r7, r8, r9)si; wherein r7, r8, r9 are independently alkyl, alkoxy, phenyl or phenoxy, optionally substituted, respectively; (r10, r11, r12)c, wherein r10, r11, r12 are independently phenyl, alkyl, optionally substituted, respectively; x═o, s, or nr13, wherein r13 is h; or alkyl or aryl, optionally substituted, respectively; or r5 is r6—co—nr13, wherein r6 and nr13 have the meaning as defined above, or wherein r6 and r13 taken together form a carbon chain having from 2 to 6 carbon atoms; r5 is a 4 to 8 membered n-containing carbon ring, wherein n is linked to m; and r4 is a residue o—si(o—)3, and represents silica to which m is linked forming a m-o—si(o—)3 moiety, preferably wherein silica is comprised in a solid support; under the proviso that a compound in which r1=2,6-diisopropylphenyl, r5 dimethylpyrrol-1-yl, r2=tbu, and r3═h is excluded.. .
Ximo Ag


05/05/16
20160122287 

Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride


A hitherto unknown crystalline form of (−)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence.. .
Gruenenthal Gmbh


05/05/16
20160122277 

Process of production of dehydrolinalyl acetate (ii)


The present invention is related to a novel and improved process for the production of dehydrolinalyl acetate (dla), which 1upac name is acetic acid 1-ethynyl-1,5-dimethyl-hex-4-enyl ester, starting from dehydrolinalool (dll), which 1upac name is 3,7-dimethyloct-6-en-1-yn-3-ol, by acetylation.. .
Dsm Ip Assets B.v.




Dimethyl topics: Physiologic, Hydrochloric Acid, Fresnel Zone, Aberration, Ophthalmic, Liquid Crystal, Imaging System, Pharmaceutically Acceptable Salt, Pharmaceutically Acceptable Salts, Chloric Acid, Tartaric Acid, Fumaric Acid, Antagonist, Bradykinin, Enantiomer

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Dimethyl for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Dimethyl with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.5309

4626

1 - 1 - 102